Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer
Claudio Isella(Candiolo Cancer Institute), Andrea Bertotti(University of Turin)
Cited by 322
Related Papers
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
|The Lancet Oncology|2016|1k
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
|Cancer Discovery|2011|948
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
|Nature Communications|2015|128